



Up to 39 Clinical Data Points Expected in 2017*

PHASE 1		PHASE 2		PHASE 3	REGISTRATION
Anetumab Ravtansine Cancer	Anetumab Ravtansine Cancer (+ pemetrexed/cisplatin)	Anetumab Ravtansine Mesothelioma (MPM)	BI-836845 Metastatic breast cancer	Guselkumab Psoriasis (VOYAGE 2)	Guselkumab Psoriasis
Anetumab Ravtansine Ovarian cancer (+ doxorubicin)	Anetumab Ravtansine Hepatic/renal impairment	BI-836845 Prostate cancer (+ enzalutamide)	Guselkumab Active psoriatic arthritis	Guselkumab Psoriasis (NAVIGATE)	
BAY-1093884 Bleeding disorders	BI-836845 Multiple cancer types (EGFR mutant NSCLC)	Tesidolumab (LFG316) Panuveitis	Tesidolumab (LFG316) Geographic atrophy (+ CLG561)	Guselkumab Pustular / Erythrodermic Psoriasis	
Gantenerumab Alzheimer's disease	Elgemtumab (LJM716) Breast cancer (+ BYL716/trastuzumab)	Elgemtumab (LJM716) Esophageal cancer (+ BYL716)	MOR103/GSK3196165 Rheumatoid arthritis	Guselkumab Moderate to severe plaque psoriasis (POLARIS)	
Tesidolumab (LFG316) Kidney Transplantation	MOR106 Inflammation	MOR103/GSK3196165 Rheumatoid arthritis	MOR103/GSK3196165 Osteoarthritis	Guselkumab Severe plaque psoriasis	
Elgemtumab (LJM716) Breast/gastric cancer	NOV-7 Eye diseases	MOR202 Multiple Myeloma	MOR208 DLBCL (+ lenalidomide)		
Utomilumab (PF-05082566) NHL/solid tumors (+ rituximab)	Utomilumab (PF-05082566) Solid tumors (+ MK-3475)	Tarextumab (OMP-59R5) Small cell lung cancer	VAY736 Rheumatoid arthritis		
Vantictumab (OMP-18R5) Lung Cancer (NSCLC)	Vantictumab (OMP-18R5) Pancreatic cancer	VAY736 Primary Sjögren's Syndrome (PD)	VAY736 Pemphigus Vulgaris		
MOR107 Lanthipeptide (Lanthic Pharma)					

 Partnered Discovery Programs
 Proprietary Development Programs